Greater awareness of biosimilars and shared decision-making among patients attending rheumatology practices in Colorado, United States: Real-world data

doi:10.5499/wjr.v10.i1.1

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 1

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11571)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series.

Item

Count

PDF

425

WORD

181

HTML

3829

Figures (1-4)

1083

Sum=5518

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

916

Download

2316

Sum=3232

Publishing Process of This Article

Item

Count

Browse

990

Download

1827

Sum=2817

Dec 28, 2020 (publication date) through Feb 16, 2026

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Rheumatology

ISSN

2220-3214

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Retrospective Study

World J Rheumatol. Dec 28, 2020; 10(1): 1-10
Published online Dec 28, 2020. doi: 10.5499/wjr.v10.i1.1

Greater awareness of biosimilars and shared decision-making among patients attending rheumatology practices in Colorado, United States: Real-world data

Rovshan Ismailov, Steven Simoens, Zaytuna Khasanova

Rovshan Ismailov, Zaytuna Khasanova, Complex Mechanisms of Disease, Aging and Trauma Research Foundation, Denver, CO 80246, United States

Steven Simoens, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven 3000, Belgium

Author contributions: Ismailov R contributed in the conception and design of the study, acquisition, analysis and interpretation of data, statistical analysis and drafting of the initial manuscript; Simoens S contributed in the analysis and interpretation of data, and critical revision for important intellectual content; Khasanova Z contributed in the conception and design of the study, acquisition, analysis and interpretation of data, and drafting of the initial manuscript;all authors approved the final version of the article.

Institutional review board statement: This study was determined as exempt by IntegReview IRB on 15 August, 2019. The study was performed in accordance with the ethical standards of the Declaration of Helsinki. Prior to the beginning of the online survey, we provided an information sheet explaining the purpose of our study, how the data will be used, and stated that the data is anonymous.

Informed consent statement: Our survey had online informed consent form. No participant signed the informed consent. Rather, by clicking on the “I agree” button below, they voluntarily agree to participate in this online survey.

Conflict-of-interest statement: This study was supported by Amgen and by the CMDAT Research Foundation. Amgen was not involved in the design and conduct of the study, selection of investigators as well as data collection and management. Dr. Rovshan Ismailov, MD, MPH, PhD received funding from Amgen to conduct this study and to develop this manuscript. He has also received financial support for educational programs from Pfizer, Amgen, Abbvie, Genentech, Novartis, Santen and Actelion. Prof. Steven Simoens, PhD is one of the founders of the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL). He was involved in a stakeholder roundtable on biologics and biosimilars sponsored by Amgen, Pfizer and MSD; he has participated in advisory board meetings for Pfizer and Amgen; and he has contributed to studies on biologics and biosimilars for Hospira, Celltrion, Mundipharma and Pfizer. Prof. Simoens is also member of the leadership team of the ISPOR Special Interest Group on Biosimilars. Dr. Zaytuna Khasanova, MD declares that she has no conflict of interest.

Data sharing statement: No data is available.

Corresponding author: Rovshan Ismailov, MD, MPH, PhD, Research Scientist, Complex Mechanisms of Disease, Aging and Trauma Research Foundation, PO Box 460722, Denver, CO 80246, United States. dr.ismailov@cmdat.org

Received: June 12, 2020
Peer-review started: June 12, 2020
First decision: October 21, 2020
Revised: October 26, 2020
Accepted: November 4, 2020
Article in press: November 4, 2020
Published online: December 28, 2020
Processing time: 199 Days and 6.3 Hours

ARTICLE HIGHLIGHTS

Research background

There are gaps in patients’ understanding of various topics related to biosimilars and shared decision-making.

Research motivation

On the other hand, there is limited published data focused on biosimilars and shared decision-making among patients attending rheumatology practices.

Research objectives

We aimed to increase knowledge and awareness of biosimilars and shared decision-making among patients diagnosed with various rheumatic diseases.

Research methods

We developed patient-friendly print materials focused on biosimilars and shared decision-making and distributed them to each participating rheumatology office in Colorado. Subsequently, we administered a survey of patients from participating offices.

Research results

After reading our print materials, most patients identified the correct answer regarding biosimilars and shared decision-making. Moreover, many patients were motivated to learn more about biosimilars and shared decision-making. On the other hand, our results indicate that many rheumatology patients in Colorado are generally not involved in discussions with their providers regarding treatment plans or options.

Research conclusions

Our educational project effectively increased the low baseline knowledge and awareness of biosimilars and shared decision-making among patients diagnosed with various rheumatic diseases.

Research perspectives

Future studies should be able to use the strengths and limitations from our current project to conduct more educational programs focused on biosimilars and shared decision-making with the ultimate goal to improve treatment adherence.